Raman Tsimafeye

Founder & CEO of VR NeuroLink

About Presenter
My name is Raman Tsimafeyeu, Founder & CEO of VR NeuroLink AI. I have over 10 years of experience in rehabilitation and entrepreneurship, leading projects at the intersection of medicine and technology. Within this project, I am responsible for strategy, partnerships, and international growth, ensuring that our solution addresses the real needs of physicians and patients in both clinics and remote care.
Title of presentation
VR NeuroLink AI: diagnostics, rehab & automation in clinic and at home
Focus Areas

StartUp & ScaleUp Zone: Where Life Science Ventures Take Off

Objective: Pitch, partner and grow – connect with investors, corporates and mentors to accelerate your journey.

Introduction: the Problem

Over 3 billion people worldwide live with neurological disorders, yet only about 10% have access to rehabilitation. Traditional tools for diagnosing CNS and balance disorders are expensive, bulky, and require specialized skills, making them inaccessible to most patients, especially in remote areas. As a result, rehabilitation often remains subjective and unmeasurable. The shortage of qualified professionals and the overload on specialists only make the problem worse.

Our goal is to change this by providing objective, measurable, and accessible diagnostics and rehabilitation, while automating the process for physicians. This not only reduces the burden on healthcare systems but also ensures equal access to care — whether in the clinic or at home.

Collaboration Offer
We are looking for partners — clinics, research institutions, and healthcare providers — to run pilot projects and validate our VR NeuroLink AI solution in real-world settings. Our platform provides objective neurodiagnostics, measurable rehabilitation, and process automation for specialists, both in clinics and remotely, powered by virtual reality and artificial intelligence. Collaboration can include joint clinical studies, co-development of rehabilitation protocols, and integration with existing healthcare systems. In return, partners gain early access to a unique, cost-effective technology for objective neurodiagnostics and measurable rehabilitation, while also contributing to reducing the global care gap.